Skip to main content

Proof of Principle of the best-in-class therapeutic mRNA cancer vaccine

Project description

New vaccine for HPV16-positive cancer tested

The EU-funded TIGER project will demonstrate the benefits of a novel mRNA cancer vaccine platform optimised for intravenous administration into patients. The antigens that will be used to deliver proof of principle comprise mRNAs encoding the proteins E6 and E7 of the human papillomavirus strain 16 (HPV16) and TriMix mRNAs that act as an adjuvant to stimulate dendritic cells to initiate strong T-cell responses. The study will be in patients with recurrent HPV16-positive cancer without and with a PD-1 checkpoint inhibitor. Safety, immunogenicity and clinical benefit will be key endpoints for this study. Once validated, the platform will be readily translatable to a wide range of cancers using other tumour antigens.

Call for proposal

H2020-SC1-BHC-2018-2020

See other projects for this call

Sub call

H2020-SC1-2020-Two-Stage-RTD

Coordinator

ETHERNA IMMUNOTHERAPIES
Net EU contribution
€ 5 094 401,25
Address
Galileilaan 19
2845 Niel
Belgium

See on map

Region
Vlaams Gewest Prov. Antwerpen Arr. Antwerpen
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 12 421 045,75

Participants (7)

SAGA DIAGNOSTICS AB
Sweden
Net EU contribution
€ 186 187,50
Address
Scheelevagen 2, Mv-401
223 81 Lund

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Södra Sverige Sydsverige Skåne län
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 0,00
STICHTING VUMC
Netherlands
Net EU contribution
€ 241 226,25
Address
De Boelelaan 1117
1081 HV Amsterdam

See on map

Region
West-Nederland Noord-Holland Groot-Amsterdam
Activity type
Research Organisations
Non-EU contribution
€ 0,00
CLINIQUE UNIVERSITAIRE SAINT-LUC ASBL
Belgium
Net EU contribution
€ 311 435,00
Address
Avenue Hippocrate 10
1200 Bruxelles

See on map

Region
Région de Bruxelles-Capitale/Brussels Hoofdstedelijk Gewest Région de Bruxelles-Capitale/ Brussels Hoofdstedelijk Gewest Arr. de Bruxelles-Capitale/Arr. Brussel-Hoofdstad
Activity type
Other
Non-EU contribution
€ 0,00
EUROPEAN CANCER PATIENT COALITION
Belgium
Net EU contribution
€ 223 125,00
Address
Rue Montoyer 40
1000 Bruxelles

See on map

Region
Région de Bruxelles-Capitale/Brussels Hoofdstedelijk Gewest Région de Bruxelles-Capitale/ Brussels Hoofdstedelijk Gewest Arr. de Bruxelles-Capitale/Arr. Brussel-Hoofdstad
Activity type
Other
Non-EU contribution
€ 0,00
ONCORADIOMICS
Belgium
Net EU contribution
€ 400 000,00
Address
Clos Chanmurly 13
4000 Liege

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Région wallonne Prov. Liège Arr. Liège
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 0,00
CERATIUM BV
Netherlands
Net EU contribution
€ 221 812,50
Address
Veemkade 240
1019 HD Amsterdam

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
West-Nederland Noord-Holland Groot-Amsterdam
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 0,00
PATERGRUS BVBA
Belgium
Net EU contribution
€ 221 812,50
Address
Sparhoekdreef 57
9880 Aalter

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Vlaams Gewest Prov. Oost-Vlaanderen Arr. Gent
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 0,00